

[View this email in your browser](#)



MORE TIME, MORE OPTIONS

CLINICAL TRIALS NEWSLETTER

PRESENTED BY **FIGHTCRC**

WITH SUPPORT FROM



MERCK

More time. More options. More progress. From research shared at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting to Fight CRC's newly updated *Path to a Cure 2026* report, this month's issue highlights the work shaping a better future for patients and families.

We want to hear from you!

*What do you want to see in our
Clinical Trials Newsletter?*

LET US KNOW!


FEATURED STORY

ASCO 2026 COLORECTAL CANCER RESEARCH RECAP

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together researchers, clinicians, advocates, and patients to share the latest advances in cancer research over 5 days. This year's meeting featured important colorectal cancer research updates in targeted therapies, immunotherapy, ctDNA testing, and biomarker-driven treatment strategies. While many findings are still being studied,

they reflect continued progress toward more personalized care based on a patient's tumor biology. Explore [Fight CRC's ASCO Annual Meeting recap](#) to learn what these developments may mean for patients, families, and future clinical trials.

RESEARCH HIGHLIGHTS FROM ASCO 2026



Happening today: Join Fight CRC for a webinar discussing key colorectal cancer research presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. Together, patient advocates and research experts will explore emerging clinical trials, biomarker-driven care, and evolving treatment strategies that may help shape the future of colorectal cancer treatment and survivorship.

Hear from Dr. Christopher Cann, MD, and Allison Rosen, a colorectal cancer survivor, longtime research advocate, and member of Fight CRC's Research Advocacy Training and Support (RATS) community, as they break down the latest findings and what they could mean for the colorectal cancer community.

JOIN US TODAY AT 1 PM ET

[Listen to the audio version of this article!](#)

CLINICAL TRIAL ROUNDUP

This month's Clinical Trial Round Up highlights research presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, including studies exploring immunotherapy combinations, biomarker-informed treatment strategies, ctDNA-guided care, and next-generation targeted therapies. These studies reflect the continued movement toward more personalized approaches to colorectal cancer care and may help inform future clinical trial opportunities and treatment discussions. Visit our full roundup for patient-friendly summaries, key takeaways, and questions to discuss with your care team.

[READ THE FULL LIST OF JUNE CLINICAL TRIALS](#)

***Disclaimer:** Inclusion in this list does not imply endorsement or a guaranteed benefit. Always consult your healthcare provider to determine whether a clinical trial is appropriate for you.*

SPOTLIGHT

Ahead of ASCO 2026, Fight CRC asked the colorectal cancer community what questions they wanted researchers to address, from treatment options and recurrence risk to insurance coverage and long-term side effects. While not every question was answered, the conference provided valuable updates on several topics that matter most to patients and survivors.

[EXPLORE THE KEY TAKEAWAYS](#)

BEHIND THE RESEARCH

Fight CRC's newly updated [Path to a Cure 2026](#) report is a patient-informed roadmap focused on accelerating colorectal cancer research, advancing equitable access to care, and improving outcomes across prevention, treatment, survivorship, and

recurrence. The report highlights emerging areas including early-age onset colorectal cancer, biomarker testing, ctDNA/MRD monitoring, survivorship, and precision medicine while identifying ongoing gaps that continue to impact patients and families.

PATH TO A CURE 2026 REPORT

ACTION AND AWARENESS



HELP SECURE FUNDING FOR CRC RESEARCH

Fight CRC advocates helped make a major impact this year. Through emails, phone calls, and meetings with lawmakers, advocates secured support from 90 bipartisan members of Congress for a Colorectal Cancer Research Program within the Department of Defense, a more than **40% increase** from last year. This growing support is an important step toward advancing colorectal cancer research and expanding future funding opportunities.

Want to make your voice heard? [Join our next Advocacy Action Hour on July 16, at 8:30 p.m. ET](#) and learn how you can help drive change for the colorectal cancer community.

[Prefer Listening? Play the Audio Version](#)



[Take the Quiz!](#)

[Ask Now!](#)

[Search Now!](#)

DONATE TO SUPPORT OUR RESEARCH

Thank you to our sponsors for this month's Clinical Trials:



Johnson & Johnson



© Copyright 2026 Fight Colorectal Cancer
FightCRC.org

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe](#)